HC Wainwright & Co. Reiterates Buy on Milestone Pharmaceuticals, Maintains $25 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Milestone Pharmaceuticals (NASDAQ:MIST) and maintained a $25 price target, as stated by analyst Patrick Trucchio.
May 16, 2024 | 11:52 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Milestone Pharmaceuticals and maintained a $25 price target, indicating continued confidence in the company's potential.
The reiteration of a Buy rating and maintenance of a $25 price target by a reputable analyst firm like HC Wainwright & Co. is a strong positive signal for investors. It suggests confidence in the company's future performance and potential for stock price appreciation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100